Table 3.

Five-year cumulative incidence of PDR as reported in previous population-based studies and the current study

Study population and location	Dates of enrollment	Follow-up (years)*	Age range (years)	Total, N	Patients with new DM2 diagnosis, n	Cumulative incidence of PDR within 5 years, n (%)
White
U.S. (present study)	2007–2010	5	≥18	47,267	47,267	775 (1.6)
Blue Mountains, Australia	1992–1994	5	≥49	139	Did not report	Did not stratify results by duration of DM2
Melbourne, Australia	1992–1994	5	≥40	121	42	Did not stratify results by duration of DM2
San Luis Valley, CO	1984–1988	4.8	20–74	72	Did not report	Did not stratify results by duration of DM2
Southern WI	1980–1982	4	≥30	485 Insulin users	96†	4%‡
				502 Noninsulin users	225†	3%‡
Black
U.S. (present study)	2007–2010	5	≥18	9,085	9,085	176 (1.9)
Nakuru, Kenya	2007–2008	6	≥50	156	89	Did not stratify results by duration of DM2
Barbados	1988–1992	4	40–84	407	43	0 (0)
Hispanic
U.S. (present study)	2007–2010	5	≥18	10,507	10,507	220 (2.1)
Los Angeles, CA	2000–2003	4	≥40	775	36	1 (2.8)
San Luis Valley, CO	1984–1988	4.8	20–74	172	Did not report	Did not stratify results by duration of DM2
Asian
U.S (present study)	2007–2010	5	≥18	2,648	2,648	38 (1.4)
Shanghai, China	2007	5	20–90	322	6	Did not stratify results by duration of DM2
Chennai, India	2003–2006	4	≥40	958	244†	2 (0.8)§

DM2, type 2 diabetes.

^*Certain studies have longer follow-up, but for the purposes of identifying the 5-year incidence of PDR, the data interval closest to this time period was chosen. For studies with variable follow-up, the median follow-up is reported.

^†These patients had 0–4 years of DM2 at baseline, making average duration >5 years at follow-up.

^‡Exact n not provided.

^§Data reported were severe non-PDR or PDR.